share_log

玮俊生物科技(00660)发布中期业绩股东应占亏损673.4万港元 同比收窄14.01%

Weijun Biotechnology (00660) announced interim results. Shareholders' share loss of HK$6.734 million narrowed 14.01% year-on-year

Zhitong Finance ·  Feb 29 17:28

According to the Zhitong Finance App, Weijun Biotechnology (00660) announced results for the six months ended December 31, 2023. The group achieved revenue of HK$190 million during the period, a decrease of 53.01% year on year; loss due to company owners during the period was HK$6.734 million, a decrease of 14.01% year on year; basic loss per share was HK$3.93.

According to the announcement, the decline in revenue was due to a decrease in market consumption and demand during the period.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment